X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3232) 3232
Newsletter (132) 132
Newspaper Article (76) 76
Publication (33) 33
Book Chapter (20) 20
Magazine Article (14) 14
Dissertation (6) 6
Conference Proceeding (4) 4
Transcript (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
apixaban (3479) 3479
rivaroxaban (2177) 2177
dabigatran (1789) 1789
warfarin (1572) 1572
humans (1482) 1482
atrial fibrillation (1341) 1341
anticoagulants (1229) 1229
stroke (850) 850
administration, oral (704) 704
cardiac & cardiovascular systems (650) 650
anticoagulants - therapeutic use (641) 641
male (621) 621
female (609) 609
thromboembolism (551) 551
aged (547) 547
edoxaban (532) 532
atrial fibrillation - drug therapy (520) 520
hematology (518) 518
anticoagulants - administration & dosage (508) 508
prevention (505) 505
peripheral vascular disease (499) 499
safety (482) 482
venous thromboembolism (465) 465
anticoagulants - adverse effects (459) 459
stroke - prevention & control (427) 427
risk factors (405) 405
middle aged (404) 404
atrial-fibrillation (401) 401
risk (387) 387
atrial fibrillation - complications (371) 371
pharmacology & pharmacy (368) 368
care and treatment (365) 365
hemorrhage - chemically induced (363) 363
anticoagulation (362) 362
management (355) 355
bleeding (351) 351
stroke prevention (351) 351
treatment outcome (343) 343
cardiac arrhythmia (337) 337
pyrazoles - therapeutic use (337) 337
pyridones - therapeutic use (336) 336
oral anticoagulants (328) 328
research (328) 328
dabigatran etexilate (322) 322
medicine, general & internal (321) 321
analysis (316) 316
thrombosis (312) 312
patients (311) 311
efficacy (303) 303
direct oral anticoagulants (285) 285
drug therapy (267) 267
medicine & public health (266) 266
therapy (263) 263
abridged index medicus (262) 262
cardiology (262) 262
aged, 80 and over (255) 255
factor xa inhibitor (251) 251
stroke - etiology (250) 250
medical research (249) 249
warfarin - therapeutic use (245) 245
thrombin (243) 243
medicine, experimental (234) 234
pyridones - administration & dosage (230) 230
pyrazoles - administration & dosage (228) 228
hemorrhage (224) 224
pharmacokinetics (224) 224
aspirin (211) 211
clinical trials (211) 211
fibrillation (211) 211
dosage and administration (209) 209
thromboprophylaxis (207) 207
mortality (206) 206
pyridones - adverse effects (202) 202
metaanalysis (201) 201
pyrazoles - adverse effects (201) 201
factor xa inhibitors (200) 200
enoxaparin (196) 196
factor xa inhibitors - therapeutic use (161) 161
internal medicine (161) 161
retrospective studies (159) 159
vitamin k - antagonists & inhibitors (157) 157
usage (156) 156
adult (152) 152
antithrombotic therapy (151) 151
blood coagulation - drug effects (149) 149
double-blind (149) 149
warfarin - adverse effects (149) 149
heart (148) 148
venous thromboembolism - drug therapy (148) 148
rivaroxaban - therapeutic use (147) 147
pharmacodynamics (146) 146
health aspects (142) 142
randomized controlled trials as topic (142) 142
surgery (142) 142
risk assessment (140) 140
beta-alanine - analogs & derivatives (138) 138
physical fitness (136) 136
reversal (132) 132
factor xa inhibitors - adverse effects (127) 127
factor xa inhibitors - administration & dosage (126) 126
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3250) 3250
German (115) 115
Spanish (72) 72
French (61) 61
Russian (43) 43
Czech (22) 22
Japanese (21) 21
Portuguese (14) 14
Hungarian (10) 10
Italian (8) 8
Polish (5) 5
Slovenian (4) 4
Korean (2) 2
Norwegian (2) 2
Romanian (2) 2
Turkish (2) 2
Chinese (1) 1
Croatian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis and haemostasis, ISSN 0340-6245, 11/2016, Volume 116, Issue 5, pp. 975 - 986
In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs) available for stroke prevention in non valvular atrial... 
Rivaroxaban | Warfarin | Dabigatran | Non-valvular atrial fibrillation | Major bleeding | Apixaban | EFFICACY | SAFETY | rivaroxaban | apixaban | ASPIRIN | warfarin | STROKE | major bleeding | ORAL ANTICOAGULANTS | dabigatran | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY
Journal Article
Circulation journal : official journal of the Japanese Circulation Society, ISSN 1347-4820, 2011, Volume 75, Issue 8, pp. 1852 - 1859
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4814 - 4814
Abstract Introduction: MM pts have one of the highest risks of TE among cancer pts. Use of IMiDs plus dex further increases this risk. Guidelines recommend... 
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 06/2017, Volume 56, Issue 6, pp. 1072 - 1082
Summary The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) patients... 
Coagulation and Fibrinolysis | EFFICACY | RIVAROXABAN | GUIDELINES | RISK | stroke | non-valvular atrial fibrillation | warfarin | DABIGATRAN | THERAPY | major bleeding | Apixaban | DISEASE | PERIPHERAL VASCULAR DISEASE | COMPLICATIONS | OUTCOMES | HEMATOLOGY
Journal Article
American family physician, ISSN 0002-838X, 05/2019, Volume 99, Issue 10, p. 653
Journal Article
British journal of haematology, ISSN 0007-1048, 2017, Volume 176, Issue 5, pp. 833 - 835
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 25, pp. 2413 - 2424
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2014, Volume 111, Issue 8, pp. 276 - 286
Summary It was the aim of this study to determine prognosis of incidentally detected ambulatory atrial fibrillation (IA-AF) and its response to antithrombotic... 
Blood Coagulation, Fibrinolysis and Cellular Haemostasis | POPULATION | BENEFIT | DABIGATRAN | MANAGEMENT | STROKE RISK | WARFARIN | RIVAROXABAN | PERIPHERAL VASCULAR DISEASE | APIXABAN | HEMATOLOGY
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 12, pp. 1131 - 1141
Journal Article
Australian prescriber, ISSN 0312-8008, 08/2019, Volume 42, Issue 4, pp. 123 - 126
Journal Article
Revista española de cardiologia, ISSN 0300-8932, 08/2015, Volume 68, Issue 8, pp. 680 - 690
Introduction and objectives Cost-effectiveness analysis of apixaban (5 mg twice daily) vs acenocoumarol (5 mg/day) in the prevention of stroke in patients with... 
Cost-effectiveness | Nonvalvular atrial fibrillation | Apixaban | Acenocoumarol
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 05/2018, Volume 118, Issue 5, pp. 842 - 851
Abstract Oral factor Xa inhibitors are increasingly used for anticoagulation, but there is no approved reversal agent. Prothrombin complex concentrate (PCC)... 
Coagulation and Fibrinolysis | antagonists and inhibitors | atrial fibrillation | haemorrhage | rivaroxaban | apixaban | HEALTHY-SUBJECTS | VITAMIN-K ANTAGONISTS | ATRIAL-FIBRILLATION | REVERSAL | BODY-WEIGHT | PHARMACOKINETICS | WARFARIN | INTRACEREBRAL HEMORRHAGE | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY
Journal Article
Blood, ISSN 1528-0020, 2014, Volume 124, Issue 15, pp. 2450 - 2458
TSOACs are associated with less major bleeding, fatal bleeding, clinically relevant nonmajor bleeding, and total bleeding. The meta-analysis does not show... 
DABIGATRAN | THERAPY | EFFICACY | SAFETY | VS. WARFARIN | RIVAROXABAN | EXTENDED TREATMENT | APIXABAN | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | ATRIAL-FIBRILLATION | Vitamin K - antagonists & inhibitors | Anticoagulants - administration & dosage | Administration, Oral | Humans | Middle Aged | Adult | Female | Male | Hemorrhage - chemically induced | Anticoagulants - adverse effects
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 380, Issue 16, pp. 1509 - 1524
Journal Article